-Reuters
Scholar Rock To Present Phase 3 SAPPHIRE Trial Design At The 17th International Congress On Neuromuscular Diseases
Scholar Rock (NASDAQ:SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced an e-poster